xml version="1.0" encoding="UTF-8"?        Document  

false0001579241  0001579241   2020-02-06 2020-02-06    0001579241  alle:ThreePointFivePercentSeniorNotesDue2029Member    2020-02-06 2020-02-06    0001579241  us-gaap:CommonStockMember    2020-02-06 2020-02-06  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________________________

FORM 8-K 

____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of The

Securities Exchange Act of 1934

Date of Report – February 6, 2020 

(Date of earliest event reported)

____________________________________________

ALLEGION PUBLIC LIMITED COMPANY 

(Exact name of registrant as specified in its charter)

____________________________________________

[DATA_TABLE_REMOVED]

Block D 

Iveagh Court 

Harcourt Road 

Dublin 2, Ireland 

(Address of principal executive offices, including zip code)

(353)(1) 2546200 

(Registrant’s phone number, including area code)

N/A

(Former name or former address, if changed since last report)

____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the

registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

[DATA_TABLE_REMOVED]

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02Departure of Directors or Certain Oﬃcers; Election of Directors; Appointment of Certain Oﬃcers; Compensatory Arrangements of Certain Oﬃcers

On February 6, 2020, the Board of Directors of Allegion plc (the “Company”) appointed Steven C. Mizell to the Board of Directors. Mr. Mizell, age 60, is the Executive Vice President and Chief Human Resources Officer at Merck & Co., Inc. 

The Board of Directors has determined that Mr. Mizell is an independent director under the New York Stock Exchange listing standards and the Company's Corporate Governance Guidelines. 

Mr. Mizell will serve as a member of the Audit and Finance Committee, Compensation Committee, and the Corporate Governance and Nominating Committee. 

Mr. Mizell will participate in the non-employee director compensation program, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 18, 2019.

Item 9.01Financial Statements and Exhibits

(d) Exhibits

Exhibit

No. Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document in Exhibit 101)

SIGNATURE 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

[DATA_TABLE_REMOVED]